Drugs that prolong QTc interval may potentiate cardiovascular effects. Use with extreme caution.
Source: NLP:arformoterol tartrate
Brand names: Arformoterol Tartrate
Route: Respiratory (Inhalation)
Contraindications
4 CONTRAINDICATIONS Arformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled cortisteroid is contraindicated in patients with asthma [see Warnings and Precautions (5)]. Arformoterol tartrate inhalation solution is not indicated for the treatment of asthma. Arformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. (4) Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (4)
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women. Arformoterol tartrate should only be used during pregnancy if the expected benefit to the patient outweighs the potential risk to the fetus. Women should be advised to contact their physician if they become pregnant while taking arformoterol tartrate. In animal reproduction studies with arformoterol administered by the oral route to rats and rabbits at exposures approximately 370 and 8,400 times the adult exposure at the maximum recommended human daily inhalation dose (MRHDID) of 15 mcg every 12 hours, respectively, there were findings of structural abnormalities, embryofetal and infant mortality, and alterations of growth. These adverse effects generally occurred at large multiples of the MRHDID when arformoterol was administered by the oral route to achieve high systemic exposures. No evidence of fetal harm was observed in rabbits at an exposure approximately 4,900 times the MRHDID. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Labor or Delivery: The potential effect of arformoterol tartrate on labor and delivery is unknown. Because of the potential for beta-agonists interference with uterine contractility, use of arformoterol tartrate inhalation solution during labor should be restricted to whom the benefits clearly outweigh the risk. Data Animal Data In an embryofetal development study in which pregnant rats received doses of 1,000, 5,000 or 10,000 mcg/kg/day from gestation days 6 to 17, arformoterol was shown to be teratogenic based upon findings of omphalocele (umbilical hernia), a malformation, in rat fetuses at exposures approximately 370 times adult exposure at the MRHDID (on an AUC basis with maternal
11 interactions on record
Drugs that prolong QTc interval may potentiate cardiovascular effects. Use with extreme caution.
Source: NLP:arformoterol tartrate
May potentiate cardiovascular effects of arformoterol. Use with extreme caution.
Source: NLP:arformoterol tartrate
May potentiate cardiovascular effects of arformoterol. Should be administered with extreme caution.
Source: NLP:arformoterol tartrate
Xanthine derivative may potentiate hypokalemia. Concomitant use may increase heart rate and systolic blood pressure. Use with caution.
Source: NLP:arformoterol tartrate
Non-potassium sparing diuretics may cause ECG changes and hypokalemia that can be worsened by beta-agonists. Use with caution.
Source: NLP:arformoterol tartrate
May potentiate hypokalemia or ECG changes. Use with caution.
Source: NLP:arformoterol tartrate
Non-potassium sparing diuretics may cause ECG changes and hypokalemia that can be worsened by beta-agonists. Use with caution.
Source: NLP:arformoterol tartrate
May decrease effectiveness and block bronchodilatory effects of arformoterol. Use with caution and only when medically necessary.
Source: NLP:arformoterol tartrate
Loop or thiazide diuretics can worsen ECG changes and hypokalemia. Caution advised in co-administration.
Source: NLP:arformoterol tartrate inhalation solution
Xanthine derivative may potentiate hypokalemia. Concomitant use associated with increased heart rate (2-3 bpm) and systolic blood pressure (6-8 mm Hg). Use with caution.
Source: NLP:arformoterol tartrate
May potentiate hypokalemia or ECG changes. Use with caution.
Source: NLP:arformoterol tartrate